2011
Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer
Mehra R, Serebriiskii IG, Dunbrack RL, Robinson MK, Burtness B, Golemis EA. Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer. Drug Resistance Updates 2011, 14: 260-279. PMID: 21920801, PMCID: PMC3195944, DOI: 10.1016/j.drup.2011.08.002.Peer-Reviewed Original ResearchConceptsEGFR/ErbB inhibitorsControl of EGFRPost-translational modificationsErbB family proteinsNew agentsSTAT proteinsFamily proteinsTransmembrane receptorsSquamous cell carcinomaLigand availabilityEffective therapeutic combinationsNew therapeutic strategiesPI3KErbB inhibitorsClinical benefitCell carcinomaMajor research goalNeck cancerProteinCause of resistanceValuable therapyTherapeutic combinationsTherapeutic strategiesTherapeutic inhibitionClinical development
2006
Novel targets in pancreatic cancer: focus on future paths to therapy
Cohen SJ, Burtness BA. Novel targets in pancreatic cancer: focus on future paths to therapy. Expert Opinion On Therapeutic Targets 2006, 10: 771-775. PMID: 16981833, DOI: 10.1517/14728222.10.5.771.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsDrug Delivery SystemsGeorgiaHumansPancreatic NeoplasmsSignal TransductionConceptsPancreatic cancerNew therapeuticsRational clinical trialsTobacco-related malignanciesDismal overall survivalPancreatic cancer pathogenesisPreclinical model systemsAdvanced diseaseOverall survivalCytotoxic therapyHER2 inhibitionClinical trialsTherapeutic increasesClinical dataClinical testingTissue factorNew casesCancer pathogenesisNovel targetCancerNew targetsTherapyEqual numberTherapeuticsMalignancy